United Services Automobile Association Invests $876,000 in United Therapeutics Corporation $UTHR

Key Points

• United Services Automobile Association acquired a new position in United Therapeutics Corporation, purchasing 2,855 shares valued at approximately $876,000 in the 1st quarter.
• Several other large investors have also increased their stakes in United Therapeutics, with institutional investors now owning 94.08% of the company’s stock.
• Analysts have mixed views on United Therapeutics, with target prices ranging from $328.00 to $500.00, and a consensus rating of "Moderate Buy."

United Services Automobile Association acquired a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 2,855 shares of the biotechnology company's stock, valued at approximately $876,000.

A number of other hedge funds have also added to or reduced their stakes in UTHR. Vaughan Nelson Investment Management L.P. purchased a new position in United Therapeutics during the 1st quarter valued at $101,354,000. Nuveen LLC purchased a new position in United Therapeutics during the 1st quarter valued at $83,533,000. Amundi increased its position in United Therapeutics by 198.8% during the 1st quarter. Amundi now owns 350,193 shares of the biotechnology company's stock valued at $107,635,000 after purchasing an additional 232,988 shares during the period. GAMMA Investing LLC increased its position in United Therapeutics by 29,415.2% during the 1st quarter. GAMMA Investing LLC now owns 221,954 shares of the biotechnology company's stock valued at $68,422,000 after purchasing an additional 221,202 shares during the period. Finally, Invesco Ltd. increased its position in United Therapeutics by 46.1% during the 1st quarter. Invesco Ltd. now owns 465,115 shares of the biotechnology company's stock valued at $143,381,000 after purchasing an additional 146,664 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently commented on UTHR. Wells Fargo & Company boosted their target price on shares of United Therapeutics from $295.00 to $414.00 and gave the company an "equal weight" rating in a report on Wednesday, September 3rd. Bank of America boosted their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the company a "neutral" rating in a report on Tuesday, September 2nd. HC Wainwright boosted their target price on shares of United Therapeutics from $400.00 to $500.00 and gave the company a "buy" rating in a report on Friday, September 5th. Jefferies Financial Group boosted their target price on shares of United Therapeutics from $432.00 to $564.00 and gave the company a "buy" rating in a report on Tuesday, September 2nd. Finally, Oppenheimer boosted their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the company an "outperform" rating in a report on Friday, September 5th. Nine investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, United Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $438.85.

Insiders Place Their Bets

In other news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $385.21, for a total transaction of $4,237,310.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares in the company, valued at approximately $14,168,409.01. This represents a 23.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total value of $9,396,900.00. The disclosure for this sale can be found here. Insiders sold 128,816 shares of company stock worth $45,836,113 in the last three months. 10.30% of the stock is owned by company insiders.

United Therapeutics Trading Up 0.0%

United Therapeutics stock traded up $0.18 during midday trading on Friday, hitting $405.02. The stock had a trading volume of 626,423 shares, compared to its average volume of 565,230. The firm's fifty day moving average is $316.32 and its two-hundred day moving average is $307.23. The company has a market capitalization of $18.27 billion, a PE ratio of 15.81, a P/E/G ratio of 6.05 and a beta of 0.62. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $436.95.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). The firm had revenue of $798.60 million during the quarter, compared to analysts' expectations of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company's revenue was up 11.7% compared to the same quarter last year. During the same period in the prior year, the company posted $5.85 earnings per share. As a group, equities research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.